Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages OncLive's social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: rscott@onclive.com
Uptake of New Therapies Pushes Treatment Paradigm Forward in Breast Cancer
April 22nd 2022Recent developments across the breast cancer paradigm include the utilization of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer, plus neoadjuvant treatment strategies in triple-negative breast cancer.
Read More
Personalized Medicine Evolves With CDK4/6 Inhibitors, Immunotherapy, and ADCs in Breast Cancer
April 21st 2022Hadeel Assad, MD, discussed how CDK4/6 inhibitors have been implemented into practice and provided updates on key clinical trials in HER2-positive breast cancer and triple-negative breast cancer.
Read More
Research Efforts Seek to Further Explore the Potential of Uproleselan in AML
April 14th 2022Tapan M. Kadia, MD, discusses what makes uproleselan unique from other agents under investigation in acute myeloid leukemia and sheds light on the many research efforts dedicated to further exploring its use in this disease.
Read More
Pembrolizumab Maintains Survival Benefits in 4-year Follow-Up of KEYNOTE-042 in NSCLC in China
April 8th 2022First-line pembrolizumab monotherapy continued to elicit an overall survival benefit and durable tumor response vs standard-of-care platinum-based chemotherapy in Chinese patients with untreated PD-L1–positive, advanced or metastatic non–small cell lung cancer without sensitizing EGFR or ALK mutations.
Read More
Hurvitz Highlights Practice-Changing DESTINY-Breast03 Data in HER2+ Metastatic Breast Cancer
April 8th 2022Sara A. Hurvitz, MD, medical oncologist and medical director at the Jonsson Comprehensive Cancer Center Clinical Research Unit, discussed pivotal findings in the HER2-positive treatment landscape that possess the potential to change practice.
Read More
Study Reveals Increased Disparities in Cervical Cancer Screening Linked With COVID-19 Pandemic
April 7th 2022Women of all races and ethnicities who were referred to a colposcopy clinic for cervical cancer screening following an abnormal Pap smear during the COVID-19 pandemic had a higher likelihood of not adhering to their appointment compared with appointment data collected prior to the pandemic.
Read More
BTK- and Venetoclax-Based Approaches Move the Needle Forward in CLL Management
April 5th 2022Inhye Ahn, MD, discusses the evolving treatment landscape of chronic lymphocytic leukemia, the advances made with BTK inhibitors and venetoclax-based regimens, novel combination regimens under exploration, and other research efforts that are underway.
Read More
Adding Uproleselan to Chemo Could Reduce Chemotherapy-Induced Mucositis in Relapsed/Refractory AML
March 30th 2022Daniel J. DeAngelo, MD, PhD, discusses how the addition of uproleselan to various chemotherapy backbones is being investigated in ongoing clinical trials, plus the encouraging safety data tied to the lowered mucositis levels.
Read More
Geriatric Assessment May Aid Treatment Decisions for Difficult-to-Treat Multiple Myeloma
March 24th 2022Alessandra Larocca, MD, PhD, discusses the use of patient- and disease-related factors that affect treatment decisions for elderly and frail patients with relapsed/refractory multiple myeloma.
Read More
Relatlimab/Nivolumab Combo Represents ‘Paradigm-Changing’ Advance in Metastatic Melanoma
March 24th 2022Hussein A. Tawbi, MD, PhD, discusses the recent FDA approval of relatlimab/nivolumab in metastatic melanoma, the significance of the regulatory decision, and potential avenues for further exploration of the regimen.
Read More
Updated KEYNOTE-564 Data Continue to Underscore Benefit of Adjuvant Pembrolizumab in RCC
March 22nd 2022Toni K. Choueiri, MD, discusses follow-up data from the pivotal phase 3 KEYNOTE-564 examining adjuvant pembrolizumab in patients with clear cell RCC and additional areas that are ripe for further research.
Read More
Axel S. Merseburger, MD, discusses the safety and efficacy results from the phase 3b PRESIDE trial examining continued enzalutamide treatment with docetaxel in select patients with metastatic castration-resistant prostate cancer who had progressed on enzalutamide monotherapy and the significance of the data for the treatment paradigm.
Read More
Nab-Paclitaxel Plus Pembrolizumab Produces Promising Responses in Advanced Urothelial Cancer
March 22nd 2022Nab-paclitaxel plus pembrolizumab produced an encouraging overall response rate with manageable safety in patients with advanced urothelial cancer who were refractory to platinum-based chemotherapy or cisplatin ineligible, according to data from the phase 2 ABLE trial.
Read More
Regorafenib/Pembrolizumab Misses PFS End Point in MSS CRC, But Biomarker Analyses Are Ongoing
March 21st 2022Afsaneh Barzi, MD, PhD, discusses the safety and efficacy of regorafenib in combination with pembrolizumab in patients with MSS colorectal cancer and describes potential next steps for further exploration of novel combinations in this population.
Read More
Frederick Locke, MD, discusses the phase 3 ZUMA-7 trial examining axicabtagene ciloleucel in the second-line treatment of patients with relapsed/refractory large B-cell lymphoma, safety and efficacy findings with the therapy, and the significance of the data that have been reported to date.
Read More
Addressing Inequities in Cancer Care Starts With Awareness
March 21st 2022Alexander B. Olawaiye, MD, discusses how social and biological determinants can affect care outcomes across cancer subtypes and what steps community and academic oncologists can take to ensure these disparities are recognized.
Read More
Uproleselan Plus Chemotherapy Continues to Show Promise in AML
March 17th 2022The addition of uproleselan to standard chemotherapy improved improve response rates and reduced chemotherapy-induced mucositis in patients with newly diagnosed and relapsed/refractory acute myeloid leukemia in a phase 1/2 trial.
Read More
Evolving Technology Behind ADCs Could Improve Benefit in Advanced Ovarian Cancer
March 11th 2022Michael Birrer, MD, PhD, discusses how new technology has transformed ADCs, how upifitamab rilsodotin could have a role in treating patients with ovarian cancer, and why the NaPi2B biomarker could be a vital target.
Read More
Phase 1/2 FELIX Trial to Determine Obe-Cel Potential in Adult Patients With ALL
March 10th 2022Claire Roddie, MD, PhD, discusses how the phase 1/2 FELIX trial could impact the treatment landscape for acute lymphoblastic leukemia, how CAR T-cell therapies have evolved, and what challenges remain in making these treatments more accessible for patients.
Read More
Eleni Efstathiou, MD, PhD, discussed the combination of niraparib and abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations, results from the MAGNITUDE trial, and next steps for research.
Read More
Bispecific Antibodies Show Potential After Relapse on CAR T-cell Therapy in Myeloma
March 2nd 2022Oliver Van Oekelen, MD, MSc, discusses findings from a retrospective study that evaluated treatment and efficacy outcomes in patients with relapsed or refractory multiple myeloma who experienced disease progression after BCMA-directed CAR T-cell therapy.
Read More